Clinical trial · no report yet · Phase 3
NCT05675410
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- NCT05675410 ↗
- Recruiting
- National Cancer Institute (NCI)
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- Interventions
- Biospecimen Collection; Bleomycin Sulfate; Brentuximab Vedotin; Computed Tomography; Cyclophosphamide; Dacarbazine; Doxorubicin Hydrochloride; Etoposide; Etoposide Phosphate; Fludeoxyglucose F-18; Involved-site Radiation Therapy; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography; Prednisolone; Prednisone; Procarbazine Hydrochloride; Questionnaire Administration; Vinblastine Sulfate; Vincristine Sulfate
- Arms
- Arm A (ABVD) · Active comparator
- Arm B (ABVD, brentuximab vedotin, nivolumab) · Experimental
- Arm C (ABVD, eBEACOPP or eBPDac, ISRT) · Experimental
- Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT) · Experimental
- Arm E (ABVD, AVD) · Experimental
- Arm F (ABVD, brentuximab vedotin, nivolumab) · Experimental
- Arm G (ABVD, eBEACOPP or eBPDac, ISRT) · Experimental
- Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT) · Experimental
- Enrollment
- 1,875 (estimated)
- Primary outcomes
- Progression-free survival (PFS) in rapid early responder (RER) patients
- PFS in slow-early responder (SER) patients
- Sponsor
- National Cancer Institute (NCI)
- Start
- May 11, 2023
- Primary completion
- Apr 28, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT05675410 · updated Oct 9, 2026
Publications
linked from the registry- Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28. PubMed 37505794